Skip to main content
. 2022 Aug 12;15:4487–4494. doi: 10.2147/IDR.S373773

Table 1.

Comparison of Patients Who Did and Did Not Receive Carbapenems as Antibiotic Prophylaxis

Carbapenem Group (n = 27) Non-Carbapenem Group (n = 78) p
Age (years) (media [±SD]) 48.8±12.1 48.2±11.4 0.818
Sex, male 22 (81.5%) 60 (76.9%) 0.622
BMI 25.4±6.8 26.9±8.3 0.415
Pre-LT ICU stay 12 (44.4%) 17 (21.8%) 0.023
Child–Pugh Score 12.0±1.2 11.6±1.3 0.162
MELD score (media [±SD]) 35.2±3.9 33.4±3.5 0.030
Underlying liver disease*
 HBV 21 (77.8%) 59 (75.6%) 0.822
 HCC 0 (0%) 1 (1.2%) 1.000
 Alcohol 5 (18.5%) 5 (6.4%) 0.120
 AIH 0 (0%) 6 (7.7%) 0.335
 PBC 0 (0%) 3 (3.8%) 0.567
 Others 3 (11.1%) 12 (15.4%) 0.755
Graft type 0.382
 DBD 9 (33.3%) 15 (19.2%)
 DBCD 5 (18.5%) 12 (15.4%)
 DCD 13 (48.1%) 50 (64.1%)
 Living donor 0 (0.0%) 1 (1.3%)
Cold ischemia time (min), media (±SD) 547.5±137.7 523.4±164.4 0.528
Warm ischemia time (min), media (±SD) 9.0±11.0 10.4±9.2 0.545
Intraoperative bleeding of ≥1500 mL 15 (55.5%) 27 (34.6%) 0.056
Vasopressor support within 24 h after LT 8 (29.6%) 3 (3.8%) 0.001
Intra-abdominal hemorrhage 2 (7.4%) 4 (5.1%) 0.646
Vascular complications 0 (0%) 4 (5.1%) 0.570
Biliary complications 2 (7.4%) 7 (9.0%) 1.000
Reoperation 5 (18.5%) 11 (14.1%) 0.582
Ventilation for >72 h 15 (55.6%) 14 (17.9%) 0.000
Renal replacement therapy for >3 days 10 (37.0%) 16 (20.5%) 0.086
Infection within 30 days after LT 18 (66.7%) 30 (38.5%) 0.011
CRO infection 5 (18.5%) 9 (11.5%) 0.345

Note: *Some patients presented more than one cause of liver disease.

Abbreviations: AIH, autoimmune hepatitis; BMI, body mass index; CRO, carbapenem-resistant organism; DBD, donation after brain death; DBCD, donation after brain death followed by circulatory death; DCD, donation after circulatory death; ICU, intensive care unit; LT, liver transplantation; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; MELD, Model for End-Stage Liver Disease; PBC, primary biliary cirrhosis; SD, standard deviation.